Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/3860
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation
Liu Hongling.
He Xi.
Wang Yudong.
Zhou Shuangnan.
Zhang Dali.
Zhu Jiye.
He Qiang.
Zhu Zhijun.
Li Guangming.
Sun Libo.
Wang Jianli.
Cheng Gregory.
Liu Zhenwen.
Lau George.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1007/s12072-020-10043-z
Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.
Hepatology International
2020
Artículo
https://link.springer.com/content/pdf/10.1007/s12072-020-10043-z.pdf
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
1105369.pdf718.83 kBAdobe PDFView/Open